Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.75%
#2 0G 0G +29.50%
#3 SAFEcoin SAFEcoin +27.44%
#4 Seeker Seeker +23.54%
#5 Pons Pons +21.03%
#6 Zora Zora +20.06%
#7 VVS Finance VVS Finance +18.18%
#8 Full Moon Full Moon +17.70%
#9 Axelar Axelar +17.50%
#10 Concordium Concordium +17.01%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing). Inc.

TransThera Sciences (Nanjing). Inc.

2617
Classifica tra le azioni #13149
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company,... TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Prezzo delle azioni
$1.30
Capitalizzazione di mercato
$516.38M
Variazione (1 giorno)
-2.21%
Variazione (1 anno)
-81.27%
Paese
CN
Scambia TransThera Sciences (Nanjing). Inc. (2617)

Categoria

Healthcare
EPS per TransThera Sciences (Nanjing). Inc. (2617)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di TransThera Sciences (Nanjing). Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per TransThera Sciences (Nanjing). Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH